ResMed Inc. (RMD): Today's Featured Health Services Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

ResMed ( RMD) pushed the Health Services industry lower today making it today's featured Health Services laggard. The industry as a whole closed the day up 0.4%. By the end of trading, ResMed fell $1.19 (-2.5%) to $45.54 on heavy volume. Throughout the day, 2,674,295 shares of ResMed exchanged hands as compared to its average daily volume of 1,040,600 shares. The stock ranged in price between $44.89-$46.50 after having opened the day at $46.36 as compared to the previous trading day's close of $46.73. Other companies within the Health Services industry that declined today were: Urologix ( ULGX), down 25.0%, ERBA Diagnostics ( ERB), down 5.9%, Iridex Corporation ( IRIX), down 5.5% and Oculus Innovative ( OCLS), down 5.4%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. ResMed has a market cap of $6.8 billion and is part of the health care sector. The company has a P/E ratio of 22.3, above the S&P 500 P/E ratio of 17.7. Shares are up 12.4% year to date as of the close of trading on Wednesday. Currently there are 4 analysts that rate ResMed a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front, Medical Action Industries ( MDCI), down 9.3%, Thermogenesis Corporation ( KOOL), down 8.7%, Opko Health ( OPK), down 6.2% and LifePoint Hospitals ( LPNT), down 4.9% , were all gainers within the health services industry with Baxter International ( BAX) being today's featured health services industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker